The effect of fibroblast growth factors and advanced glycation end-products on the intima-media complex thickness in patients with coronary heart disease and type 2 diabetes

Objective.
To determine the levels of fibroblast transforming growth factor (TGF?1), basic fibroblast growth factor (?-FGF), markers of nonspecific inflammatory response (interleukin-6 (IL-6)), C-reactive protein (CRP), advanced glycation end-products (AGEs) and their receptors (RAGEs) and to study their effect on the intima-media complex (IMC) thickness in patients with coronary heart disease (CHD) and type 2 diabetes, depending on carbohydrate metabolism compensation.
Materials and Methods.
37 patients with CHD underwent a general clinical examination, analysis of the carbohydrate and lipid metabolism parameters and the renal function, and also were evaluated with instrumental methods of analysis (echocardiography, coronary angiography and duplex scanning of the brachiocephalic arteries). To determine the level of the analyzed parameters, blood samples were taken from the aorta during coronary angiography and concomitantly from the cubital vein in all patients.
Results.
The presence of diabetes mellitus (DM) in patients with CHD was found to be associated with a more severe atherosclerotic disease of the coronary and brachiocephalic vessels. A direct correlation between the degree of stenosis and the level of fibroblast growth factors, inflammatory factors, and advanced glycation end-products was found. A direct correlation between AGE and TGF?1 and the lipid metabolism parameters was established. A statistically significant elevation of the studied parameters in the arterial and venous blood of patients with DM was revealed.
Conclusion.
These findings confirm the relationship between connective tissue disorders and lipid metabolism in the pathogenesis of atherosclerosis. A negative effect of hyperglycaemia on atherosclerotic changes of the vascular wall was demonstrated.

fibroblast growth factors, intima-media complex, advanced glycation end-products, diabetes, atherosclerosis

1. Ajani UA, Ford ES. Has the risk for coronary heart disease changed among U.S. adults? J Am Coll Cardiol. 2006;48:1177-1182.

2. Sang Ouk Chin, Jin Kyung Hwang, Sang Youl Rhee, Suk Chon, You-Cheol Hwang, Seungjoon Oh, Kyu Jeung Ahn, Ho Yeon Chung, Jeong-taek Woo, Sung-Woon Kim, Young Seol Kim, Ja-Heon Kang, In-Kyung Jeong. Risk Factors for the Progression of Intima-Media Thickness of Carotid Arteries: A 2-Year Follow-Up Study in Patients with Newly Diagnosed Type 2 Diabetes. Diabetes Metab J. 2013 October; 37(5): 365–374.

3. Pignoli P, Tremoli E, Poli A. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74(6): 1399-406.

4. Bots ML, Baldassarre D, Simon A, de Groot E, O'Leary DH, Riley W, Kastelein JJ, Grobbee DE. Carotid intima-media thickness and coronary atherosclerosis: weak or strong relations? Eur Heart J. 2007 Feb;28(4):398-406.

5. Eleid MF, Lester SJ, Wiedenbeck TL. Carotid ultrasound identifies high risk subclinical atherosclerosis in adults with low framingham risk scores. J Am Soc Echocardiogr. 2010;23(8):802-808.

6. Lorenz MW, Markus HS, Bots ML, Rosvall M, Sitzer M. Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation. 2007 Jan 30;115(4):459-67.

7. Tarzamni MK, Salehi R, Givian F, Farhang S. Association of carotid intima-media thickness with the presence and severity of coronary artery disease. Neurosciences 2006;11(4): 308-311.

8. Bots M.L., Hoes A.W. Koudstaal P.J., Hofman A., Grobbee D.E. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam study. Circulation, 1997; 96(5): 1432-1437.

9. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARTerial disease (SMART) study: rationale and design. Eur J Epidemiol. 1999 Oct;15(9):773-81.

10. Белоусов ЮБ, Несмараев ЖН. Эндотелиальная дисфункция как причина атеросклеротического поражения артерий при артериальной гипертензии. Фарматека.2004;6(84):62-72

11. Campistol JM, Inigo P, Jimenez W. Losartan decreases plasma levels of TGF-pi in transplant patients with chronic allograft nephropathy. Kidney Int.1999;56:714-719.

12. Herder M, Johnsen SH, Arntzen KA, Mathiesen EB. Risk factors for progression of carotid intimamedia thickness and total plaque area. А 13-year follow-up study: the Tromso study. Stroke. 2012;43(7):1818–1823.

13. Ingelsson E, Sullivan LM, Murabito JM, Fox CS, Benjamin EJ, Polak JF, Meigs JB, Keyes MJ, O’Donnell CJ, Wang TJ, D’Agostino RB Sr, Wolf PA, Vasan RS. Prevalence and prognostic impact of subclinical cardiovascular disease in individuals with the metabolic syndrome and diabetes. Diabetes. 2007;56(6):1718— 1726.

14. Zieman SJ, Vojtech M, Clattenburg L, Corretti MC, Capriotti AR, Gerstenblith G, Kass DA. Advanced glycation endproduct crosslink breaker (alagebrium) improves endothelial function in patients with isolated systolic hypertension. J Hypertens. 2007;25:577-83

15. Балахонова ТВ, Трипотень МИ, Погорелова ОА. Ультразвуковые методы оценки комплекса интима-медиа артериальной стенки. SonoAce-Ultrasound. 2010;21.

16. Sauvage M, Hinglais N, Mandet C, Badier C, Deslandes F, Michel JB Jacob MP. Localization of elastin mRNA and TGF-ß1 in rat aorta and caudal artery as a function of age. Cell Tissue Res. 1998;291:305-14

17. Fleenor BS, Seals DR, Zigler ML, Sindler AL. Superoxide-lowering therapy with TEMPOL reverses arterial dysfunction with aging in mice. Aging Cell. 2012;11:269-276.

18. Fleenor BS, Sindler AL, Eng JS, Nair DP, Dodson RB, Seals DR. Sodium nitrite de-stiffening of large elastic arteries with aging: Role of normalization of advanced glycation end-products. Exp Gerontol. 2012; 47:588-94.

19. Fleenor BS, Marshall KD, Durrant JR, Lesniewski LA, Seals DR. Arterial stiffening with ageing is associated with transforming growth factor-β1-related changes in adventitial collagen: reversal by aerobic exercise. J Physiol. 2010;588:3971-82.

20. Fleenor BS, Marshall KD, Rippe C, Seals DR. Replicative aging induces endothelial to mesenchymal transition in human aortic endothelial cells: Potential role of inflammation. J Vasc Res. 2012;49:59-64

21. Tiyyagura SR, Pinney SP. Left ventricular remodeling after myocardial infarction: past, present, and future. Mt. Sinai J. Med. 2006;73(6):840–851

22. Keeley EC, Mehrad B, Strieter RM. Fibrocytes: Bringing new insights into mechanisms of inflammation and fibrosis. International J. Biochemistry Cell Biology.2010;42:535-542.

23. Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des. 2008;14(10):979-86.

24. Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, Eckstein H, we Heemann, Staessen JA. Association between carotid diameter and the advanced glycation endproduct Nε-Carboxymethyllysine (CML). Cardiovascular Diabetology.2009;8(1):45 doi:10.1186/1475-2840-8-45

25. Steppan J, Tran H, Benjo AM, Pellakuru L, Barodka V, Ryoo S, Nyhan SM, Lussman C, Gupta G, White AR, Daher JP, Shoukas AA, Levine BD. Alagebrium in combination with exercise ameliorates age-associated ventricular and vascular stiffness. Exp Gerontol. 2012;47:565-72.

26. Basta G, Lazzerini G, Massaro M, Simoncini T, Tanganelli P, Fu C, Kislinger T, Stern DM, Schmidt AM, De Caterina R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation.2002;105:816-22.

27. Halushka MK, Selvin E, Lu J, Macgregor AM, Cornish TC. Use of human vascular tissue microarrays for measurement of advanced glycation endproducts. J Histochem Cytochem.2009;57:559-66.

28. Kass DA, Shapiro EP, Kawaguchi M, Capriotti AR, Scuteri A, deGroof RC, Lakatta EG. Improved Arterial Compliance by a Novel Advanced Glycation End-Product Crosslink Breaker. Circulation.2001;104:1464-70.

29. Coll B, Feinstein SB. Carotid intima-media thickness measurements: techniques and clinical relevance. Curr Atheroscler Rep. 2008;10:444–450.

30. Барбараш ОЛ, Авраменко ОЕ, Осокина АВ, Сумин АН, Веремеев АВ. Роль провоспалительных факторов в оценке прогноза больных с прогрессирующей стенокардией в сочетании с сахарным диабетом 2 типа. Сахарный диабет. 2012;4:39–45

31. Willemsen S, Hartog JW, Hummel YM, Posma JL, van Wijk LM, van DJ Veldhuisen, Voors AA. Сlinical and prognostic value of advanced glycation end products in chronic heart failure. European Heart Journal 2007;28:2879–2885.

32. Lautenslager GT, Shearman CW, Hud E, Cohen MP. Effects of nonenzymatic glycation and fatty acids on functional properties of human albumin. Metabolism.2011;60(12):

33. Yan SF, D'Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): a formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med. 2007 Dec;7(8):699-710.1683-1691.

34. Nin JW, Jorsal A. Higher Plasma Levels of Advanced Glycation End Products Are Associated With Incident Cardiovascular Disease and All-Cause Mortality in Type 1 Diabetes. Diabetes Care. 2011;34:442–447,

35. Hegab Z, Gibbons S, Neyses L, Mamas M. Role of advanced glucation end products in cardiovascular disease. World J.Cardiol.2012;4(4):90-102.

36. Reddy GK. AGE-related cross-linking of collagen is associated with aortic wall matrix stiffness in the pathogenesis of drug-induced diabetes in rats. Microvasc Res. 2004;68(2):132-42.

37. Lapolla A. Nonenzymatically glycated lipoprotein Apo-AI in plasma of diabetic and nephropathic patients. Ann N Y Acad Sci 2007;26:295-299

38. Hoang A. Advanced glycation end-products of apolipoprotein Apo-AI impairs its anti-atherogenic properties. Diabetologia 2007;50:1770-1779

39. Low H, Hoang A, Forbes J. Advanced glycation end-products and functionality of reverse cholesterol transport in patients with type 2 diabetes and in mouse models. Diabetologia 2012;55:2513-2521

40. Basta G, Schmidt AM, De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc Res. 2004;63(4):582-92.

41. Linden E, Cai W, He JC, Xue C, Li Z, Winston J, Vlassara H, Uribarri J. Endothelial Dysfunction in Patients with Chronic Kidney Disease Results from Advanced Glycation End Products (AGE)-Mediated Inhibition of Endothelial Nitric Oxide Synthase through RAGE Activation. Clin J Am Soc Nephrol. 2008; 3(3): 691–698.

42. Sugimoto K., Yasujima M., Yagihashi S. Role of advanced glucation end products in diabetic neuropathy. Curr. Pharm. Des. 2008;14(10):953-61.

43. Hou FF, Ren H, Owen WF, Guo ZJ, Chen PY, Schmidt AM, Miyata T, Zhang X: Enhanced expression of receptor for advanced glycation end products in chronic kidney disease. J Am Soc Nephrol.2007;15:1889–1896.

44. Uribarri J, Cai W, Peppa M, Goodman S, Ferrucci L, Striker G, Vlassara H. Circulating glycotoxins and dietary advanced glycation endproducts: Two links to inflammatory response, oxidative stress and aging. J Gerontol Med Sci 200;762:427–433.

45. Hartog JW, Voors AA,Bakker SJ. Advanced glycation endproducts and heart failure:pathophysiology and clinical implications. Eur J Heart Fail 2007;9:1146-1155

46. Simm A, Wagner J, Gursinsky T, Nass N, Friedrich I. Advanced glycation eandproducts:a biomarker for age as an outcome predictor after cardiac surgery? Exp Gerontol 2007;42:668-675

47. Semba RD, Ferrucci L, Sun K, Beck J, Dalal M, Varadhan R, Walston J, Guralnik JM, Fried LP. Advanced glycation end products and their circulating receptorspredict cardiovascular disease mortality in older community dwelling women. Aging Clin Exp Res. 2009; 21(2): 182–190.

48. Maria F, Hunt KJ, Baker NL, Lachin J, Nathan DM. Levels of Oxidized LDL and Advanced Glycation End Products–Modified LDL in Circulating Immune Complexes Are Strongly Associated With Increased Levels of Carotid Intima-Media Thickness and Its Progression in Type 1 Diabetes. Diabetes, 2011;60;582-588

49. Koyama Y. Soluble receptor for advanced glycation endproducts is a prognostic factor for heart failure. J Card Fail 2008;14:133-139

50. Raposeiras-Roubin S. Relation of soluble receptor for advanced glycation endproducts to predict mortality in patients with chronic heart failure independently of Seattle Heart Failure Score. Am J Cardiol. 2011;107:938-944

51. Raposeiras-Roubin S. Solible receptor of advanced glycation endproducts levels are related Eur J Heart Fail. 2010;12:1092-1100